Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Non-Small Cell Lung Cancer — A Special Audio Supplement


Introduction and overview of activity

Track 1: Case (Dr Picton): An 85-year-old woman with locally advanced lung adenocarcinoma, an asymptomatic brain metastasis and an isolated pelvic lesion

Long-term management of non-small cell lung cancer (NSCLC) in patients with an activating EGFR mutation

Track 2: Tumor genomic testing for patients with metastatic NSCLC
Track 3: Case (Dr Rodriguez): A 66-year-old woman with EGFR exon 21 mutation-positive metastatic lung adenocarcinoma
Track 4: Case (Dr Lobins): A 50-year-old woman receives erlotinib for Stage IV, EGFR (L858R) mutation-positive lung adenocarcinoma and experiences severe dermatologic toxicity

Recent treatment advances for patients with ALK, ROS1, RET and BRAF mutation-positive NSCLC


Track 5: Management of NSCLC with RET alterations
Track 6: Efficacy of brigatinib for ALK-rearranged metastatic NSCLC
Track 7: Pulmonary toxicity with brigatinib
Track 8: Side effects associated with crizotinib
Track 9: Sequencing of therapy for patients with ALK-rearranged metastatic NSCLC
Track 10: Case (Dr Rodriguez): A 54-year-old woman receives dabrafenib and trametinib for BRAF V600E mutation-positive metastatic lung adenocarcinoma
Track 11: Use of ALK inhibitors for patients with locally advanced ALK-rearranged NSCLC before chemoradiation therapy

Optimal integration of immune checkpoint inhibition into clinical decision-making for patients with locally advanced NSCLC

Track 12: Clinical implications of the PACIFIC trial of durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
Track 13: Selection of patients to receive durvalumab as sequential therapy after chemoradiation therapy for locally advanced NSCLC
Track 14: Risk of pneumonitis for patients with advanced NSCLC treated with immune checkpoint inhibitors
Track 15: Sequencing durvalumab for patients with locally advanced NSCLC who are receiving consolidation chemotherapy

Current role of immune checkpoint inhibitors in combination with chemotherapy and/or anti-angiogenic agents in the treatment of metastatic disease

Track 16: Case (Dr Rodriguez): A 63-year-old woman with metastatic lung adenocarcinoma receives carboplatin/paclitaxel with atezolizumab and bevacizumab on the IMpower150 trial
Track 17: Choice of first-line therapy for patients with metastatic nonsquamous NSCLC and no targetable alterations
Track 18: Case (Dr Gupta): A 61-year-old woman with a history of rheumatoid arthritis is diagnosed with metastatic lung adenocarcinoma and an EGFR exon 20 insertion
Track 19: Efficacy of checkpoint inhibitors in patients with metastatic squamous cell carcinoma
Track 20: Use of checkpoint inhibitors for solid organ transplant recipients

Potential role of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies in combination

Track 21: Case (Dr Gupta): A 75-year-old woman diagnosed in 2014 with metastatic breast cancer is found to have a small lesion in the lung 3 years later that biopsy reveals to be small cell lung cancer
Track 22: Tolerability of anti-PD-1/PD-L1 and anti-CTLA-4 antibody combinations
Matthew D Hellmann, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Vice Chair, Radiation Therapy Oncology Group
Philadelphia, Pennsylvania
Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Martin Reck, MD, PhD
Head of Department of Thoracic Oncology
Head of Clinical Trial Department
LungenClinic Grosshansdorf
Grosshansdorf, Germany
Alice Shaw, MD, PhD
Professor of Medicine
Harvard Medical School
Center for Thoracic Cancers
Massachusetts General Hospital
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida